Nanexa AB (SE:NANEXA)
:NANEXA
Want to see SE:NANEXA full AI Analyst Report?
Top Page
Nanexa AB
(NANEXA)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr3.50
▲(15.51% Upside)
Action:Reiterated
Date:05/02/26
The score is held back primarily by ongoing unprofitability and weak free-cash-flow generation, despite a conservatively financed balance sheet with minimal leverage. Technical indicators also point to a weak near-term trend, while valuation is difficult to assess given negative earnings and no provided dividend yield.
Positive Factors
Partnership- and licensing-driven business model
A licensing/partnership model centered on the PharmaShell platform creates scalable, asset-lite revenue potential via upfronts, R&D fees, milestones and royalties. This reduces capital intensity versus full commercialization and aligns incentives with pharma partners, supporting durable revenue levers if deals close.
Negative Factors
Deep negative free cash flow and ongoing cash burn
Large negative free cash flow indicates sustained cash outflows for development that exceed operating receipts, creating ongoing funding requirements. Persistent FCF deficits raise dilution or debt risks, hinder long-term investment flexibility, and make the business dependent on partner payments or new financing to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnership- and licensing-driven business model
A licensing/partnership model centered on the PharmaShell platform creates scalable, asset-lite revenue potential via upfronts, R&D fees, milestones and royalties. This reduces capital intensity versus full commercialization and aligns incentives with pharma partners, supporting durable revenue levers if deals close.
Read all positive factors
Nanexa AB (NANEXA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr689.64M
Dividend YieldN/A
Average Volume (3M)266.98K
Price to Earnings (P/E)―
Beta (1Y)0.11
Revenue Growth79.13%
EPS Growth55.77%
CountrySE
Employees13
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.10
Shares Outstanding191,036,530
10 Day Avg. Volume346,691
30 Day Avg. Volume266,979
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)6.83
Price to Sales (P/S)19.19
P/FCF Ratio-26.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr112.20M
Nanexa AB Business Overview & Revenue Model
Company Description
Nanexa AB (NANEXA) is a biotechnology company specializing in drug delivery systems, particularly in the development of its proprietary platform, NEX-20, designed to enhance the efficacy and safety of therapeutic compounds. The company operates pr...
How the Company Makes Money
Nanexa’s business model is primarily partnership- and licensing-driven around its PharmaShell drug delivery platform. The company seeks to generate revenue by collaborating with pharmaceutical and biotech companies to develop long-acting formulati...
Nanexa AB Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.90M | 36.15M | 24.36M | 29.33M | 2.86M | 2.37M |
| Gross Profit | 17.11M | -15.46M | 46.69M | 59.16M | 3.40M | 4.31M |
| EBITDA | -490.00K | -2.92M | -18.99M | -70.79M | -53.86M | -32.92M |
| Net Income | -16.42M | -11.39M | -24.91M | -76.40M | -58.57M | -36.00M |
Balance Sheet | ||||||
| Total Assets | 166.70M | 138.14M | 91.82M | 132.26M | 170.19M | 165.00M |
| Cash, Cash Equivalents and Short-Term Investments | 73.02M | 44.57M | 10.29M | 65.17M | 81.18M | 105.66M |
| Total Debt | 987.00K | 2.20M | 3.71M | 4.03M | 6.27M | 3.83M |
| Total Liabilities | 39.57M | 36.61M | 20.90M | 36.43M | 61.10M | 13.70M |
| Stockholders Equity | 127.13M | 101.53M | 70.92M | 95.83M | 109.10M | 151.29M |
Cash Flow | ||||||
| Free Cash Flow | -18.43M | -26.21M | -54.55M | -76.91M | -43.29M | -50.92M |
| Operating Cash Flow | 229.00K | -1.46M | -26.43M | -42.66M | -7.87M | -25.13M |
| Investing Cash Flow | -24.27M | -24.75M | -28.12M | -34.25M | -35.42M | -25.79M |
| Financing Cash Flow | 47.85M | 60.49M | -327.00K | 60.89M | 18.81M | 143.89M |
Nanexa AB Technical Analysis
Positive
3.03
Price Trends
3.71
Negative
3.76
Negative
2.93
Positive
Market Momentum
-0.03
Negative
47.82
Neutral
51.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NANEXA, the sentiment is Positive. The current price of 3.03 is below the 20-day moving average (MA) of 3.60, below the 50-day MA of 3.71, and above the 200-day MA of 2.93, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.82 is Neutral, neither overbought nor oversold. The STOCH value of 51.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:NANEXA.
Nanexa AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr589.85M | -14.34 | ― | ― | 9.56% | 19.12% | |
48 Neutral | kr689.64M | -11.63 | -48.65% | ― | 79.13% | 55.77% | |
45 Neutral | kr188.21M | -240.17 | -24.83% | ― | ― | 21.82% | |
43 Neutral | kr193.09M | -3.17 | -530.21% | ― | 742.87% | 40.47% | |
43 Neutral | kr33.34M | -0.51 | ― | ― | -86.56% | 8.75% | |
42 Neutral | kr160.31M | -2.22 | -90.66% | ― | ― | -32.29% |
* Healthcare Sector Average
SE:NANEXA
Nanexa AB
3.63
1.51
71.23%
SE:ALZCUR
AlzeCure Pharma AB
1.39
-1.16
-45.54%
SE:VIVE
Vivesto AB
14.40
-5.79
-28.68%
SE:KLAR
Klaria Pharma Holding AB
0.79
0.04
5.88%
SE:ENZY
Enzymatica AB
2.38
-0.59
-19.87%
SE:ERMA
Enorama Pharma AB
0.41
-2.08
-83.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.